| 引用本文: | 谢圣芳,盛梅笑,姚源璋,盖丰丰,王苏伟,王寒冰.肾宁Ⅱ号方治疗慢性肾脏病2~5期疗效观察[J].中国现代应用药学,2019,36(7):859-863. |
| XIE Shengfang,SHENG Meixiao,YAO Yuanzhang,GE Fengfeng,WANG Suwei,WANG Hanbing.Effect Observation of Shenning Ⅱ Decoction in the Treatment of Chronic Kidney Disease of Phase 2-5[J].Chin J Mod Appl Pharm(中国现代应用药学),2019,36(7):859-863. |
|
| 摘要: |
| 目的 通过病例回顾性分析，观察肾宁Ⅱ号方治疗慢性肾脏病（chronic kidney disease，CKD）2~5期对近、远期肾功能影响。方法 共198例患者纳入观察，治疗组124例（肾宁Ⅱ号方加基础治疗），对照组74例（基础治疗）。观察治疗2周时2组患者肾功能、血尿酸及肝功能等实验室指标的变化，其中82例患者（治疗组59例、对照组23例）继续治疗并随访3个月，通过血肌酐倒数（1/Scr）随时间（月）直线回归斜率b值观察远期肾功能的变化趋势，并从理论上预测3年内进入终末期肾衰（end-stage renal failure，ESRD）患者的例数。结果 近期疗效，治疗组总有效率优于对照组（66.94% vs 51.35%，P<0.05），CKD 5期及非糖尿病肾病（non-diabetic kidney disease，NDKD）患者治疗组疗效优于对照组（67.44% vs 39.13%，71.43% vs 53.49%，P<0.05）。远期疗效，治疗组b值>对照组，b值正值数>对照组，预测治疗后3年内进入ESRD患者例数低于对照组，差异均有统计学意义（P<0.05）。结论 在常规治疗基础上，应用肾宁Ⅱ号方治疗CKD 2~5期患者有助于改善NDKD患者近期肾功能，并能够延缓肾功能不全病情进展。 |
| 关键词: 慢性肾脏病 肾宁Ⅱ号 临床疗效 |
| DOI：10.13748/j.cnki.issn1007-7693.2019.07.018 |
| 分类号:R969.4 |
| 基金项目:江苏省中医药局课题资助项目（FY201510）；第三批江苏省中医临床优秀人才研修项目（苏中医科教[2017]18号） |
|
| Effect Observation of Shenning Ⅱ Decoction in the Treatment of Chronic Kidney Disease of Phase 2-5 |
|
XIE Shengfang1, SHENG Meixiao2, YAO Yuanzhang1, GE Fengfeng1, WANG Suwei3, WANG Hanbing3
|
|
1.Department of Nephrology, Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing 210028, China;2.Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China;3.Nanjing University of Chinese Medicine, Nanjing 210023, China
|
| Abstract: |
| OBJECTIVE To observe the short-term and long-term clinical effect of Shenning Ⅱ decoction in the treatment of chronic kidney disease(CKD) of phase 2-5 by retrospective analysis method. METHODS A total of 198 patients were included in the study, 124 cases in the treatment group(received Shenning Ⅱ decoction and basic treatment) and 74 cases in the control group(received basic treatment). The change of renal function, serum uric acid and liver function in 2 groups were observed at 2 weeks after treatment. Eighty-two patients(59 cases in treatment group, 23 cases in control group) were continued treatment and followed up for 3 months, and the trend of renal function was observed by linear regression of slope b of reciprocal serum creatinine(1/Scr) with time(month), and the number of patients with end-stage renal failure(ESRD) in 3 years was predicted theoretically. RESULTS The total effective rate of the treatment group was higher than the control group(66.94% vs 51.35%, P<0.05), the total effective rate of patients of CKD5 and patients of non-diabetic kidney disease(NDKD) in the treatment group was higher than that of the control group(67.44% vs 39.13%, 71.43% vs 53.49%, P<0.05). About the long-term curative effect, the treatment group b value was higher than that of the control group, the number of positive b value of the treatment group was higher than the control group, the number of cases with ESRD predicted in the 3 year was less than that in the control group. The long-term curative effect is better in the treatment group(P<0.05). CONCLUSION On the basis of routine treatment, the Shenning Ⅱ decoction can improve renal function of CKD of phase 2-5 with NDKD patients and delay the progression of renal failure patients. |
| Key words: chronic kidney disease Shenning Ⅱ decoction clinical effects |
